Evaxion A/S (EVAX)
NASDAQ: EVAX · Real-Time Price · USD
3.534
-0.726 (-17.04%)
Mar 16, 2026, 1:12 PM EDT - Market open
Evaxion Revenue
In the year 2025, Evaxion had annual revenue of $7.53M with 125.12% growth.
Revenue (ttm)
$7.53M
Revenue Growth
+125.12%
P/S Ratio
23.60
Revenue / Employee
$163,652
Employees
46
Market Cap
147.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.53M | 4.18M | 125.12% |
| Dec 31, 2024 | 3.34M | 3.27M | 4,480.82% |
| Dec 31, 2023 | 73.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Celularity | 40.58M |
| Xilio Therapeutics | 31.80M |
| Pluri | 1.34M |
| Werewolf Therapeutics | 1.14M |
| Outlook Therapeutics | 205.70K |
| Actinium Pharmaceuticals | 90.00K |
| INmune Bio | 50.00K |
EVAX News
- 9 days ago - Evaxion A/S (EVAX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Evaxion announces business update and full year 2025 financial results - GlobeNewsWire
- 11 days ago - Evaxion plans to file 2025 annual report later today - GlobeNewsWire
- 14 days ago - Evaxion to announce business update and full year 2025 financial results on March 5, 2026 - GlobeNewsWire
- 2 months ago - Evaxion expands AI-Immunology™ platform into autoimmune diseases - GlobeNewsWire
- 2 months ago - Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week - GlobeNewsWire
- 3 months ago - Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out - Benzinga
- 3 months ago - Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2 - GlobeNewsWire